Medpace Holdings, Inc.

Medpace Holdings, Inc. announced a new $1.0 billion stock repurchase authorization, replacing the previous one which was terminated. The company also reported strong third quarter and year-to-date financial results, with revenue and net income showing significant year-over-year growth. Full-year 2026 revenue guidance was also provided, indicating continued expected growth.

Medpace Holdings, Inc. reported strong financial results for the second quarter and first six months ended June 30, 2026. Revenue for Q2 increased to $707.3 million, with net income rising to $121.4 million and basic EPS at $4.31. For the six-month period, revenue reached $1.41 billion and net income was $245.2 million. The company also repurchased $294.7 million in common stock, but disclosed two class action lawsuits filed in the quarter.

Medpace Holdings, Inc. reported strong second quarter 2026 financial results, with revenue increasing 17.2% to $707.3 million and GAAP net income growing 34.4% to $121.4 million. The company also announced net new business awards of $795.7 million, resulting in a healthy book-to-bill ratio of 1.13x. Medpace provided an optimistic full-year 2026 guidance, forecasting revenue between $2.805 billion and $2.885 billion and diluted EPS between $17.25 and $17.95.

Medpace Holdings, Inc. announced the appointment of Brad W. Hansman as Executive Vice President, Operations, effective June 1, 2026. Mr. Hansman will share the role of principal operating officer with Susan E. Burwig. He will receive an annual base salary of $492,250 and will be eligible for incentive compensation plans. Mr. Hansman has been with Medpace since 2011, progressing through various finance and operations leadership roles.

Medpace Holdings, Inc. announced that stockholders approved significant amendments to its Restated Certificate of Incorporation and Bylaws at the 2026 Annual Meeting. These changes remove supermajority voting requirements and grant stockholders the right to call special meetings, subject to a 25% ownership threshold held for one year. Additionally, stockholders elected five directors, ratified Deloitte & Touche LLP as the independent auditor, and approved the advisory vote on executive compensation and a one-year frequency for future compensation votes.

Medpace Holdings, Inc. has filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The filing confirms the company's status as a large accelerated filer and includes unaudited financial statements and management's discussion and analysis. As of April 17, 2026, the company reported 28,559,689 shares of Common Stock outstanding.

Medpace Holdings, Inc. reported strong first-quarter 2026 financial results, with revenue increasing 26.5% to $706.6 million. GAAP net income rose to $123.9 million, or $4.28 per diluted share, compared to $3.67 per diluted share in the prior-year period. EBITDA also saw a significant increase of 25.9% to $149.4 million. The company secured $618.4 million in net new business awards and provided optimistic full-year 2026 guidance, forecasting revenue between $2.755 billion and $2.855 billion.